A Phase 3 interventional study of S-1 + Cisplatin (arm A) and Cisplatin (arm B) in Cervical Cancer, sponsored by Taiho Pharmaceutical Co., Ltd.. Completed at 4 sites in 3 countries. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-06-21.
Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Uterine Cervical Neoplasms with a site in Japan — 15 open to participants now, 23 under way, 3 of them phase 3. Uterine Cervical Neoplasms · Japan.
Among the 49 studies in Uterine Cervical Neoplasms with a site in Japan, this one is the 24th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2008, is one of 15 in phase 3, and was the 6th registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →15 of the 49 studies in Uterine Cervical Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
Tata Memorial Hospital · Sites in Japan, India, Thailand
Women only
Merck Sharp & Dohme LLC · Sites in Japan, United States, Argentina and 26 more countries
Ages 18+ · Women only
Tanabe Pharma America, Inc. · Sites in Japan, United States
Ages 18+
Bayer · Sites in Japan, United States, Australia and 8 more countries
Ages 18+
AstraZeneca · Sites in Japan, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 18 · Phase 3 15 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 375 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 384 across the 45 interventional studies, 506 across the 3 observational. Of the 25 that completed or were terminated, 13 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taiho Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Otsuka Holdings Co., Ltd. has 2 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Uterine Cervical Neoplasms with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT06533059Alterome Therapeutics, Inc.A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | 2026-12-29 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT03386734Centre Hospitalier Universitaire de BesanconInternational Validation Study of Sentinel Node Biopsy in Early Cervical Cancer | 2027-05 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 49 studies in Uterine Cervical Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or persistent carcinoma of the cervix.
Japanese phase II study of S-1 in cervical cancer suggested promising response rate and good tolerability. Since recommended chemotherapy for metastatic or recurrent cervical carcinoma is either single-agent Cisplatin or Cisplatin-based combination chemotherapy, this is designed to evaluate the efficacy and safety of S-1 in combination with Cisplatin compared with single-agent Cisplatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If the patient have received chemotherapy, radiotherapy or chemoradiotherapy as previous treatment, following interval must have elapsed from the last administration of treatment:
If there have been residual disease in previously irradiated field and without disease progression since the (chemo) radiotherapy, 90 days must have elapsed after the last administration of irradiation.
Patients who have adequate hematologic, hepatic and renal functions as defined below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
S-1 + Cisplatin (arm A)
Drug: S-1 + Cisplatin (arm A)
Cisplatin (arm B)
Drug: Cisplatin (arm B)
Drug pages: Tegafur · Gimeracil · Oxonic Acid · Cisplatin
S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
Overall Survival
Time frame: From the date of randomization to death from any cause, assessed up to 296 events or the end of November 2015, whichever was earlier, each three months
Progression Free Survival, Safety
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: About Progression free survival, from the randomization to disease progression or death, whichever came first, assessed up to until primary outcome came each three months, and about safety, from the first treatment to 30 days after the last treatment
375 patients were randomized to Arm A (189) or Arm B (186); of these, 364 patients(188 and 176, respectively) received study treatment. 11 patients (1 and 10, respectively) did not receive allocated intervention because of 'withdrew consent(1 and 6, respectively)' , 'ineligible criteria(3 in Arm B)', or 'investigator's discretion(1 in Arm B)'.
| Milestone | S-1 + Cisplatin (Arm A) | Cisplatin (Arm B) |
|---|---|---|
| Started | 188 | 176 |
| Completed | 188 | 176 |
| Not completed | 0 | 0 |
| months | S-1 + Cisplatin (Arm A) | Cisplatin (Arm B) |
|---|---|---|
| Overall Survival | 21.9 (18.6 to 25.8) | 19.5 (17.0 to 24.3) |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | S-1 + Cisplatin (Arm A) | Cisplatin (Arm B) |
|---|---|---|
| Progression Free Survival, Safety | 7.3 (6.7 to 8.1) | 4.9 (4.4 to 5.7) |
Collected over From the date of the first treatment to 30 days after the last treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| S-1 + Cisplatin (Arm A) | 7/188 (3.7%) | 72/188 (38.3%) | 188/188 (100%) |
| Cisplatin (Arm B) | 3/175 (1.7%) | 34/175 (19.4%) | 172/175 (98.3%) |
| Event | S-1 + Cisplatin (Arm A) | Cisplatin (Arm B) |
|---|---|---|
| Neutrophil count decreasedInvestigations | 12/188 | 0/175 |
| Haemoglobin decreasedInvestigations | 10/188 | 5/175 |
| ThrombosisVascular disorders | 10/188 | 2/175 |
| DiarrhoeaGastrointestinal disorders | 9/188 | 0/175 |
| Urinary tract infectionInfections and infestations | 5/188 | 4/175 |
| Platelet count decreasedInvestigations | 5/188 | 0/175 |
| Ureteric obstructionRenal and urinary disorders | 5/188 | 2/175 |
| VomitingGastrointestinal disorders | 4/188 | 0/175 |
| PyrexiaGeneral disorders | 4/188 | 0/175 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/188 | 0/175 |
| Event | S-1 + Cisplatin (Arm A) | Cisplatin (Arm B) |
|---|---|---|
| NauseaGastrointestinal disorders | 153/188 | 134/175 |
| Neutrophil count decreasedInvestigations | 148/188 | 65/175 |
| Haemoglobin decreasedInvestigations | 147/188 | 87/175 |
| Decreased appetiteMetabolism and nutrition disorders | 141/188 | 105/175 |
| FatigueGastrointestinal disorders | 109/188 | 79/175 |
| VomitingGastrointestinal disorders | 103/188 | 71/175 |
| DiarrhoeaGastrointestinal disorders | 94/188 | 51/175 |
| White blood cell count decreasedInvestigations | 92/188 | 52/175 |
| Platelet count decreasedInvestigations | 90/188 | 26/175 |
| ConstipationGastrointestinal disorders | 61/188 | 48/175 |
A total of 364 (188 in Arm A; 176 in Arm B) received study treatment. Two patients in Arm B were excluded in the efficacy analysis, because of insufficient informed consent, and missing efficacy data.
| Age, Continuous(years) | S-1 + Cisplatin (Arm A) | Cisplatin (Arm B) | Total |
|---|---|---|---|
| Median | 55 (27 to 84) | 52.5 (28 to 81) | 54 (27 to 84) |
| Sex: Female, Male(Participants) | S-1 + Cisplatin (Arm A) | Cisplatin (Arm B) | Total |
|---|---|---|---|
| Female | 188 | 174 | 362 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | S-1 + Cisplatin (Arm A) | Cisplatin (Arm B) | Total |
|---|---|---|---|
| South Korea | 52 | 49 | 101 |
| Japan | 110 | 105 | 215 |
| Taiwan | 26 | 20 | 46 |
The record gives a start of Sep 2008, a primary completion of Dec 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2019, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid · Cisplatin
Taiho Pharmaceutical Co., Ltd. →